Accelerate Diagnostics, Inc. (0H8E.L)

0,9245 +0,0640 (+7,44%) Börsenschluss: 05:44PM BST

Accelerate Diagnostics, Inc.

3950 South Country Club Road
Suite 470 4th Floor
Tucson, AZ 85714
United States
520 365 3100
https://acceleratediagnostics.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 134

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jack Phillips	CEO, President & Director	595k	N/A	1966
Mr. David Patience	Chief Financial Officer	285,27k	N/A	1986
Mr. Lawrence Michael Mertz	Chief Technology Officer	335,94k	N/A	1963
Ms. Maya Gowri	Senior VP & Head of Operations	N/A	N/A	N/A
Laura Pierson	Investor Relations Officer	N/A	N/A	N/A
Mr. John Meduri	Chief Strategy Officer	N/A	N/A	N/A
Mr. Chris Thode	Senior Vice President of US Commercial	N/A	N/A	N/A
Ms. Rita Boukamel	Senior VP & Head of EMEA	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Corporate Governance

Accelerate Diagnostics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 10, Vorstand: 3, Shareholderrechte: 2, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.